Cardiovascular disease (CVD) is the leading contributor to global mortality1. While myocardial infarction and stroke are the most common manifestations of CVD, vascular diseases of the lower limbs, such as peripheral arterial disease (PAD) and diabetic foot disease, contribute substantially to the personal, social, and healthcare burden of CVD2,3,4. Importantly, these disease states are characterized by microvascular and macrovascular dysfunction5 that contribute to symptoms (e.g., intermittent claudication), functional impairment, poor mobility as well as social isolation and reduced quality of life6. Historically, upper-limb vascular assessment techniques have been used as a measure of systemic vascular function and associated cardiovascular risk; however, these methods are potentially not sensitive to local impairments in lower limb vascular function7,8. While there is currently a range of techniques used to assess vascular function in the lower limb, such as flow-mediated dilatation (FMD) and contrast-enhanced ultrasound, each method has disadvantages and limitations, such as equipment cost, operator skill, or the need for invasive venous access. For these reasons, there is a need for standardized and effective techniques to evaluate lower limb vascular (dys)function that can be more readily implemented in research and clinical settings.
Continuous wave near-infrared spectroscopy (CW-NIRS) is a non-invasive, low-cost, and portable method that quantifies the relative changes in hemoglobin oxygenation in vivo. As the NIRS oxygenated and deoxygenated hemoglobin signals are derived from the small (<1 mm in diameter) vessels, local skeletal muscle metabolism and microvascular function are able to be evaluated9. Specifically, the tissue saturation index (TSI) [TSI = oxygenated hemoglobin/ (oxygenated hemoglobin + deoxygenated hemoglobin) x 100], provides a quantitative measure of tissue oxygenation9. When measured before, during, and after occlusion and reactive hyperemia, the changes in TSI indicate 'end-organ' vascular responsiveness, relative to the pre-occlusion baseline. Importantly, this method is sensitive to alterations in muscle microvascular responsiveness and perfusion associated with ageing10, disease progression11, and clinical interventions (e.g., revascularization surgery12,13 or exercise rehabilitation14,15,16,17) in individuals with, or at risk of microvascular dysfunction.
The availability of NIRS systems has led to a rapid rise in the number of research studies reporting microvascular function18. However, differences in reactive hyperemia testing protocols, omission of detailed, repeatable NIRS methods, as well as a lack of uniformity in the description, presentation, and analysis of NIRS response parameters make comparisons across individual trials challenging. This limits the collation of data for meta-analysis and the formulation of clinical assessment recommendations9,15.
Therefore, in this article, we describe our laboratory's standardized NIRS and vascular occlusion testing protocols for the assessment of lower limb reactive hyperemia. By disseminating these methods, we aim to contribute to the improved standardization and repeatability of data collection procedures and harmonized reporting.